| abstract |
Proper combination of alteration of CDR region amino acid sequence, alteration of variable region amino acid sequence, and alteration of normal region amino acid sequence provides better antigen neutralization, pharmacokinetics (plasma retention), immunogenicity, safety, and physical properties than TOCILIZUMAB. Successful creation of a therapeutic agent for arthritis rheumatoid (rheumatic arthritis), pediatric chronic arthritis, or Castleman's disease using the IL-6 receptor antibody as an active ingredient. |